Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Tecentriq
CAS: 1380723-44-3
Pharmacological action and mechanism
Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells and may contribute to the inhibition of anti-tumor immune responses in tumor microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1 receptors and antigen presentation showed that the cells inhibited the activity of cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1 and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune responses, including activation of anti-tumor immune responses, does not induce antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition of pd-l1 activity leads to reduced tumor growth.
We can customize according to customer's requirement
if you have any question pls mail us or call us
